Asmanex(Mometasone Furoate)
OGN
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Organon & Co.
$6.5M
Medicare cost, 2024
$6.5M
Medicare cost, 2024
Medicare drug plans spent $6.5 million on Asmanex (mometasone furoate) in 2024, for 35,687 prescriptions and refills filled by 11,728 patients. Spending fell 55% from 2023 to 2024. Pennsylvania accounts for the most spending ($700,479, 11% of the total). It is made by Organon & Co. (OGN).
Medicare cost, 2024
$6.5M
-55.4% from 2023
Prescriptions
36K
$182.39 per claim
Patients
12K
10,954 prescribers
Total spending, 2024
$6.5M
$555.09 per patient
Questions and answers
How much does Medicare spend on Asmanex?
Medicare prescription drug plans paid $6.5M for Asmanex in 2024, for 35,687 prescriptions and refills to 11,728 patients (down 55.4% from 2023). The average cost per claim was $182.39.
Which state spends the most on Asmanex?
Pennsylvania had the highest Medicare cost for Asmanex in 2024: $700K for 4,035 claims, followed by New York ($456K).
Who prescribes Asmanex the most?
Christopher Faber, pulmonary disease in Pittsburgh, PA, had the highest Medicare cost for Asmanex in 2024: 73 claims costing $9,415.
Who makes Asmanex?
Asmanex is made by Organon & Co. (OGN), listed in the Medicare spending data as Organon LLC.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Asmanex was $6.5M in 2024, after a high of $15.7M in 2022.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Asmanex, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Christopher Faber Pittsburgh, PA | Pulmonary Disease | 73 | 16 | $9,415 |
| Schuman Tam San Francisco, CA | Allergy/ Immunology | 34 | Under 11 | $8,142 |
| Kaiser G Lim Rochester, MN | Pulmonary Disease | 21 | Under 11 | $7,809 |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 29 | Under 11 | $7,595 |
| John Russomanno Hartford, CT | Pulmonary Disease | 39 | Under 11 | $7,344 |
| Eric J Schenkel Bethlehem, PA | Allergy/ Immunology | 21 | Under 11 | $7,177 |
| Richard F Kucera Greensburg, PA | Pulmonary Disease | 39 | 11 | $6,856 |
| Kenneth A Johns Coon Rapids, MN | Allergy/ Immunology | 46 | Under 11 | $6,758 |
| Jose J Gomez Idabel, OK | Family Practice | 54 | 11 | $6,725 |
| Michael Schatz San Diego, CA | Allergy/ Immunology | 28 | Under 11 | $6,514 |
| Natalie A Brixey Tishomingo, OK | Family Practice | 50 | Under 11 | $6,277 |
| Yasir Hatahet Fond Du Lac, WI | Pulmonary Disease | 43 | Under 11 | $6,258 |
| Richard N Krinsky Winsted, CT | Pulmonary Disease | 40 | Under 11 | $6,023 |
| Keith Harmon St Louis Park, MN | Pulmonary Disease | 31 | Under 11 | $5,980 |
| Tyree L Seals Fort Smith, AR | Internal Medicine | 56 | 13 | $5,907 |
| Rajesh C Patel Riverhead, NY | Internal Medicine | 20 | 11 | $5,489 |
| Mark Lowenthal Orland Park, IL | Allergy/ Immunology | 19 | Under 11 | $5,338 |
| Lianne L Lin Beaverton, OR | Pulmonary Disease | 23 | Under 11 | $5,250 |
| Donna M Romito Norwich, CT | Pulmonary Disease | 19 | Under 11 | $5,207 |
| Karen M Schaller Bethlehem, PA | Nurse Practitioner | 19 | Under 11 | $5,060 |
| Ramesh B Avula Lansing, MI | Allergy/ Immunology | 14 | Under 11 | $5,035 |
| Bryan Farthing Anchorage, AK | Physician Assistant | 19 | Under 11 | $4,970 |
| Brian P Burlew Bethlehem, PA | Internal Medicine | 25 | 11 | $4,894 |
| Gary W Price Lakeland, FL | Allergy/ Immunology | 11 | Under 11 | $4,871 |
| John J Solic State College, PA | Pulmonary Disease | 32 | Under 11 | $4,869 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 11,471 | 42,541 | 12,433 | $16.0M |
| 2023 | 10,438 | 38,006 | 11,074 | $14.6M |
| 2024 | 10,954 | 35,687 | 11,728 | $6.5M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Organon LLC | 35,699 | $6.5M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 5
- RxNorm concept IDs
- 746803, 746804, 746810, 746811, 746812
- Application numbers
- NDA021067
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 58,425 side-effect reports named mometasone furoate, the active ingredient of Asmanex (reports from 2003 on). 28,021 of them (48.0%) were serious, 2,032 named a death and 12,739 named a hospital stay. The reactions named most often were no adverse event, product quality issue and dyspnoea. 13,443 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
58,425
2,168 in 2025 (-3.9% from 2024)
Serious
48.0%
28,021 reports
Deaths named
2,032
3.5% of reports
Hospital stays
12,739
21.8% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Asmanex?
58,425 reports from 2003 through September 2026 named mometasone furoate, the active ingredient of Asmanex. 28,021 of them (48.0%) were serious, 2,032 named a death and 12,739 named a hospital stay.
What are the most reported side effects of Asmanex?
7,963 reports named no adverse event, the reaction named most often, followed by product quality issue (7,829) and dyspnoea (5,789). In the last 5 years the reaction named most often was device malfunction (1,950 reports). A report can name several reactions.
How many side-effect reports named Asmanex in 2025?
2,168 reports were received in 2025 (-3.9% from 2024). 2026 so far: 3,088 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Asmanex caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Asmanex caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with mometasone furoate: Mometasone Furoate, Asmanex Hfa, Mometasone Furoate*
- Makers on the stock market:
OGN·OGN drug pipeline - Drug approvals (14 approvals on file for mometasone furoate) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (mometasone furoate) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.